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Historical Background
Since the first empirical attempts at the begin-
ning of the twentieth century,1 specific
immunotherapy (SIT) for allergic rhinitis has been
administered via the subcutaneous route. The clin-
ical efficacy of this treatment was immediately rec-
ognized, and its use rapidly spread. At the same
time, attempts were made to administer the aller-
genic extracts via different routes, and in fact,
oral immunotherapy was first proposed in the
early 1900s.2,3 Later, during the 1950s, local
bronchial desensitization was suggested and inves-
tigated4,5 whereas sublingual immunotherapy
(SLIT) appeared only in 1986.6 The main stimu-
lus to the development of noninjection routes was
the problem of the safety of injected SIT, which
became of primary relevance after the formal and
detailed report of numerous deaths due to subcu-
taneous SIT.7 Nevertheless, independent of the
safety issue, local nasal immunotherapy (LNIT)
has been extensively investigated since the 1970s,8,9
first in the United States and later in Italy. Within
the last 20 years, reports from more than 60 con-
trolled trials of various noninjection routes have
been published in peer-reviewed journals, but in
1998, on the basis of an extensive review of the
literature, a panel of experts from the World Health
Organization concluded that only SLITand LNIT
are viable alternatives to therapy by the injection
route.10 These conclusions were soon confirmed
in a position paper by the European Academy of
Allergology and Clinical Immunology11 and in
the ARIA (Allergic Rhinitis and Its Impact on
Asthma) study document.12 Currently, SLIT is
prescribed in many European countries whereas
the use of LNIT is progressively decreasing,
mainly because of technical limitations.
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Abstract
The possibility of producing local hyposensitization by administering allergens via mucosal routes was
envisaged at the beginning of 1900, and local nasal immunotherapy has been extensively studied since
the 1970s. Presently, there are 21 randomized controlled trials being conducted with the most common
allergens, consistently showing the clinical efficacy of local nasal immunotherapy for rhinitis. Other
advantages are that it has an optimal safety profile and can be self-administered at home by the patient.
Moreover, there are several data from animal models and from humans that confirm the immunomod-
ulatory effect of intranasally administered antigens. On the other hand, local nasal immunotherapy
seems to be effective only on rhinitis symptoms and requires a particular technique of administration.
For these reasons, its clinical use is progressively declining in favour of the sublingual route although
nasal immunotherapy is validated in official documents and remains a viable alternative to injection.
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Practical Aspects
LNIT is the administration (by spray) of grad-
ually increasing amounts of allergen (build-up
or up-dosing phase) into the nasal cavity until a
maintenance dose is reached. The maintenance
dose is then given continually at variable inter-
vals to maintain  “hyposensitization” and to
reduce symptoms due to natural exposure to the
allergen. The few nasal vaccines are commer-
cialized in Europe and standardized either bio-
logically or immunologically. Like the extracts
used for subcutaneous immunotherapy, they are
labelled in arbitrary units, according to in-house
references. LNIT is given as a nasal spray that
can be either an aqueous solution or a dry pow-
der. LNIT can be administered either presea-
sonally (stopping at the beginning of the season),
“pre-coseasonally” (stopping at the end of the
season), or continually. Pre-coseasonal schedules
are the choice for pollen allergy whereas con-
tinuous treatments are preferred for perennial
allergens. The build-up phase usually lasts about
4 to 6 weeks, and the vaccine is prepared in
separate vials or blisters at increasing concen-
trations (Figure 1). Simplified schedules of
administration (steady dosage) have also been
proposed, to make LNITmore “patient friendly.”
Detailed education of the patient is mandatory
because LNIT is self-administered at home by
the patient. Administration requires good train-
ing and some precautions so that inhalation into
the deep airways (ie, the patient’s vocalizing
while spraying) is avoided. Dry-powder cap-
sules used with a spraying device make admin-
istration quite easy (Figure 2). Some authors
have suggested premedication with nasal cro-
molyn before each dose, but there is no strict sci-
entific support for this.
Efficacy and Safety
To date, there have been 21 randomized double-
blind placebo-controlled studies with LNIT(Table
1).13–33 All but two16,24 invariantly documented a
significant reduction of symptoms and/or drug
intake scores. In this regard, the clinical efficacy
of LNIT for rhinitis symptoms was comparable
to that of subcutaneous SIT. In parallel, several
trials demonstrated a measurable reduction of the
nasal response to specific challenge,24–32 con-
firming the effectiveness of hyposensitization.
The large majority of LNIT studies were con-
ducted among subjects with pollinosis, and the
treatment was proved to be effective with all the
major pollens (including birch, ragweed, grasses,
and Parietaria judaica). There were also four
studies performed with a mite extract, three with
favourable results20,31,32 and one with negative
results,24 but in this latter study, LNITwas admin-
Figure 1 Example of an administration schedule for
local nasal immunotherapy (LNIT) with an aqueous
extract prepared at different concentrations. UB = bio-
logic units; Wk = weeks.
Figure 2 Diagram of a delivery device for extracts pre-
pared as dry-powder capsules (Allerkin, Lofarma S.p.A,
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istered for 3 months only. Few studies (all with
positive results) were carried out with children,27,32
and there is insufficient experience with the pedi-
atric age group. LNIT seems to be effective only
locally (ie, for rhinitis symptoms); there is no
proof that it is also able to treat asthma. There is
one study (uncontrolled, with 43 pollinosis
patients) that shows a reduction of nonspecific
bronchial hyperresponsiveness following LNIT.34
Concerning the duration of clinical efficacy, the
only available follow-up of a randomized con-
trolled trial suggested that LNIT does not main-
tain its clinical efficacy once it is discontinued and
that a preseasonal course is needed every year.35
On the other hand, a prospective observational
study (not randomized and not controlled) docu-
mented 3 to 5 years of long-lasting clinical effi-
cacy in 22 patients after discontinuation of LNIT.36
Aqueous extracts of unmodified allergens are
highly effective, but they also provoke mild LNIT-
induced rhinitis whereas treatment with aller-
goids (chemically modified allergens) is almost
devoid of local side effects (however, allergoids
are less potent). These facts, observed in the ear-
liest studies, raised some concerns about the clin-
ical use of LNIT37 because although the symptoms
were reduced during the allergen exposure, they
were present (even if mild) at every LNITadmin-
istration. Extracts that are prepared as dry pow-
der solved the problem; the granules (with a diam-
eter of 40–50 µm) allow a uniform deposition on
the nasal mucosa and do not provoke clinical
symptoms. In fact, no side effects or only negli-
gible side effects were reported in all the studies
that used dry powders. In one study, three patients
withdrew because of bronchospasm after admin-
istration, but this side effect was attributed to
incorrect technique (ie, improper inhalation of
the allergen).22 LNIT seems to be well tolerated
and to have a reasonable safety profile.11,12 
Table 1  Double-Blind Placebo-Controlled Studies of Local Nasal Immunotherapy
No. of 
Patients
(Active/
Author, Year Age Range (yrs) Placebo) Allergen Duration Type of Extract
Johansson, 197913 Ad 12/11 Grass 14 wk Aqueous, modified
Nickelsen, 198114 16–66 38/34 Ragweed 3 mo Aqueous, modified
Welsh, 198115 13–58 18/15 Ragweed 20 wk Aqueous
Schumacher, 198216 20–53 8/7 Grass 10 wk Powder, modified
Georgitis, 198317 16–67 31/13 Grass 10 wk Aqueous, modified
Georgitis, 198418 Ad 29/16 Grass 10 wk Aqueous, modified
Andri, 199219 14–54 8/8 Parietaria 18 wk Powder, modified
Andri, 199320 15–54 11/10 Mite 12 mo Powder
Passalacqua, 199521 20–56 9/9 Parietaria 5 mo Powder
D’Amato, 199522 13–37 10/10 Parietaria 8 mo Powder
Andri, 199523 17–56 14/14 Birch 22 wk Powder
Fanales-Belasio, 199524 16–49 10/10 Mite 3 mo Aqueous
Andri, 199625 14–52 13/15 Grass 4 mo Powder
Cirla, 199626 17–44 11/11 Birch/alder 4 mo Powder
Bardare, 199627 5–15 19/20 Grass 3 mo Powder
Gaglani, 199728 18–35 13/14 Weed mix 4 mo Aqueous
Bertoni, 199929 18–43 10/10 Grass 3 mo Aqueous
Motta, 200030 13–55 55/47 Grass/mite 8 mo Aqueous
Pocobelli, 200131 16–45 22/21 Grass 4 mo Powder, modified
Marcucci, 200232 4–15 16/16 Mite 18 mo Powder, modified
Passali, 200233 16–47 18/18 Mite 8 mo Powder, modified
Ad = advanced age; wk = weeks.In the more recent studies, a simplified sched-
ule of administration was used, with a single and
steady dosage from the beginning.31,33This admin-
istration schedule is advantageous for patients
because different preparations at different con-
centrations are no longer required and because
accidental dosing mistakes are avoided. The clin-
ical equivalence between the steady dosage and the
traditional build-up was demonstrated in a ran-
domized open trial.38
Immunologic Aspects
As mentioned above, the first attempts to achieve
a selective hyposensitization of the nasal mucosa
were made at the beginning of the 1970s.8,9 The
underlying rationale was derived from the obser-
vation that hyporesponsiveness of the nasal mucosa
could be achieved after repeated stimulation with
low doses of allergen.39 From a clinical view-
point, this is the opposite of the well-known prim-
ing effect, whereby an increased mucosal response
is seen after a single administration of allergen.40
The changes in nasal allergic response over
time were confirmed in a challenge-rechallenge
study.41 In this trial, allergic patients received a
baseline nasal challenge and a rechallenge after 3,
7, 14, or 28 days. If the rechallenge was made after
3 days, the clinical response was greater than
baseline (priming effect) whereas there was a sig-
nificantly decreased response at 14 days. The 
7- and 28-day challenges evoked a clinical
response identical to that of the baseline chal-
lenge (Figure 3). In general, the local administra-
tion of allergens is supported by a number of
experimental observations in animal models, show-
ing the “tolerogenicity” of mucosal antigen deliv-
ery.42,43 In an animal model, it was seen that
mucosal administration of the antigen could select
a functionally disabled population of CD4+cells.44
Also, in animal models, intranasal administration
of antigens was found to induce an increased pro-
duction of interleukin-10,45,46 the regulatory and
antiinflammatory cytokine involved in the mech-
anisms of action of traditional SCIT.47,48Systemic
immunologic changes induced by LNITin humans
were reported only sporadically in the above-
mentioned clinical trials. In one open study of
LNIT and SCIT, it was shown that only SCIT
could induce an increase in circulating
immunoglobulin G4.49 Nevertheless, patients
treated with LNIT also showed decreased prolif-
eration of allergen-specific T-lymphocyte clones
after treatment. In one clinical trial, it was shown
that LNITis capable of modulating allergic inflam-
mation by down-regulating the expression of inter-
cellular adhesion molecule 1.35 Despite their wide
clinical use, nothing is known about the absorp-
tion and fate of SCITallergenic extracts in humans.
Indeed, their biodistribution would be of particu-
lar importance in the case of local administration.
In rats and rabbits, significant absorption of the
allergen through sublingual and nasal mucosae
has been shown.50 This is in agreement with the
increased permeability of nasal epithelium to
macromolecules that is observed in allergic sub-
jects,51 but there is still controversy concerning the
pharmacokinetics of allergens.52 In recent years,
the biodistribution of mucosal antigens was
assessed in humans with the use of a radiolabelled
purified allergen (Par j 1) and a special proce-
dure.53 With this design, it was observed that no
direct absorption of the allergen through the sub-
lingual mucosa occurs and that plasma radioac-
tivity increases only after the allergen is swal-
lowed. This is also true  for nasal administration.
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Figure 3 Graph showing how the intensity of nasal
response to rechallenge is different at different times.
If the rechallenge is made 2 weeks after the first chal-
lenge, a significant reduction in the response is seen.
Adapted from Nickelsen JAet al.41 d = days; NS =      Local Nasal Specific Immunotherapy for Allergic Rhinitis — Passalacqua and Canonica 121
In healthy volunteers, the allergen sprayed into the
nose is slowly transported by mucociliary clear-
ance towards the pharynx (Figure 4) and is pro-
gressively swallowed, but a fraction is retained for
long periods (up to 40 hours) in the mucosa.53,54
Things are partly different in allergic subjects;
the allergen is cleared from the nose faster than in
nonallergic persons, and it disappears completely
from the nose within minutes.55
Conclusions
On the basis of the literature review, it can be said
that local nasal immunotherapy (LNIT) is clearly
effective in treating allergic rhinitis because it alle-
viates symptoms and reduces the need for con-
comitant medications during natural exposure to
allergens. Another favourable aspect of LNITis its
safety, which has been repeatedly confirmed in
numerous trials. Moreover, LNITis self-adminis-
tered by patients in their homes, thus avoiding the
costs for injections and loss of time. On the other
hand, LNIT is effective only for rhinitis whereas
patients often have concomitant allergic diseases
such as asthma and conjunctivitis. In addition, a spe-
cific administration technique is needed to avoid
inhalation of the extract into the deep airways
whereas sublingual immunotherapy (SLIT) is more
easily used and has a systemic effect. For these rea-
sons, the clinical use of LNIT is progressively
declining in favour of SLIT. In Italy, LNITcurrently
accounts for about 10% of immunotherapy sales.
Nevertheless, it remains a viable alternative to
subcutaneous therapy. The optimal candidates are
adult and well-trained patients with pollen-induced
rhinitis and patients who refuse injections or who
cannot tolerate the subcutaneous regimen.
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